Therapeutic targeting in the silent era: advances in non-viral siRNA delivery
dc.contributor.author | Guo, Jianfeng | |
dc.contributor.author | Fisher, Karen A. | |
dc.contributor.author | Darcy, Raphael | |
dc.contributor.author | Cryan, John F. | |
dc.contributor.author | O'Driscoll, Caitríona M. | |
dc.contributor.funder | Science Foundation Ireland | en |
dc.contributor.funder | Irish Research Council for Science Engineering and Technology | en |
dc.date.accessioned | 2013-01-29T10:11:16Z | |
dc.date.available | 2013-01-29T10:11:16Z | |
dc.date.copyright | 2010 | |
dc.date.issued | 2010-04 | |
dc.date.updated | 2013-01-17T10:53:32Z | |
dc.description.abstract | Gene silencing using RNA-interference, first described in mammalian systems almost a decade ago, is revolutionizing therapeutic target validation efforts both in vitro and in vivo. Moreover, the potential for using short interfering RNA (siRNA) as a therapy in its own right is also progressing at a significant pace. However, the widespread use of such approaches is contingent on having appropriate systems to achieve clinically appropriate, safe, and efficient delivery of siRNA. There are many physicochemical and biological barriers to such delivery, and a growing emphasis on the design and characterisation of non-viral technologies that will overcome these barriers and expedite targeted delivery. This review discusses the considerations and challenges associated with use of siRNA-based therapeutics, including stability and off-target effects. Speculation is made on the properties of an ideal delivery system and the non-viral delivery approaches used to date, both in vitro and in vivo, are classified and discussed. Moreover, the ability of cyclodextrin-based delivery vectors to fulfil many of the criteria of an ideal delivery construct is also elaborated. | en |
dc.description.sponsorship | Science Foundation Ireland (Strategic Research Cluster (Irish Drug Delivery Network); Science Foundation Ireland (Centre for Science Engineering & Technology); Science Foundation Ireland (Research Frontiers Programmes); Irish Research Council for Science Engineering and Technology (Embark initiative) | en |
dc.description.status | Peer reviewed | en |
dc.description.version | Accepted Version | en |
dc.format.mimetype | application/pdf | en |
dc.identifier.citation | GUO, J., FISHER, K. A., DARCY, R., CRYAN, J. F. & O'DRISCOLL, C. 2010. Therapeutic targeting in the silent era: advances in non-viral siRNA delivery. Molecular BioSystems, 6, 1143-1161. doi: 10.1039/c001050m | en |
dc.identifier.doi | 10.1039/c001050m | |
dc.identifier.endpage | 1161 | en |
dc.identifier.issn | 1742-206X | |
dc.identifier.journaltitle | Molecular Biosystems | en |
dc.identifier.startpage | 1143 | en |
dc.identifier.uri | https://hdl.handle.net/10468/933 | |
dc.identifier.volume | 6 | en |
dc.language.iso | en | en |
dc.publisher | Royal Society of Chemistry | en |
dc.relation.uri | http://pubs.rsc.org/en/content/articlelanding/2010/mb/c001050m | |
dc.rights | © 2010 Royal Society of Chemistry | en |
dc.subject | siRNA-based therapeutics | en |
dc.subject | Non-viral technologies | en |
dc.subject | Cyclodextrin | en |
dc.subject.lcsh | Gene silencing | en |
dc.subject.lcsh | Drug delivery systems | en |
dc.title | Therapeutic targeting in the silent era: advances in non-viral siRNA delivery | en |
dc.type | Article (peer-reviewed) | en |